Abstract
The lack of blood flow during cerebral ischemic conditions results in multiple and intricate pathophysiological mechanisms including excitotoxicity, oxidative stress, neuroinflammation, white matter injury, and blood–brain barrier impairment. Despite numerous experimental studies that have been conducted in preclinical settings, current treatments for cerebral ischemia including mechanical and pharmacological therapies are limited, and often accompanied by significant side effects. Therefore, it is necessary to investigate new strategies for treating these conditions. Cannabidiol, the most abundant non-psychotomimetic compound obtained from Cannabis sativa L., Cannabaceae, is a pleiotropic compound acting in a variety of molecular targets and may affect many pathophysiological processes resulting in improvement of cerebral ischemia outcomes. In this review, we summarize the main effects of cannabidiol in different animal models of cerebral ischemia and discuss some of its putative mechanisms of neuroprotection.
Graphical Abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, Rueda M, Pertwee RG, Castillo AI, Romero J, Martínez-Orgado J (2008) Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res 64:653–658. https://doi.org/10.1203/PDR.0b013e318186e5dd
Anderson CA, Arciniegas DB (2010) Cognitive sequelae of hypoxic-ischemic brain injury: a review. NeuroRehabilitation 26:47–63. https://doi.org/10.3233/NRE-2010-0535
Atalay S, Dobrzyńska I, Gęgotek A, Skrzydlewska E (2020) Cannabidiol protects keratinocyte cell membranes following exposure to UVB and hydrogen peroxide. Redox Biol 36:101613. https://doi.org/10.1016/j.redox.2020.101613
Back T, Otto D, Kittner D, Schüler OG, Hennerici MG, Mennel HD (2007) Failure to improve the effect of thrombolysis by memantine in a rat embolic stroke model. Neurol Res 29:264–269. https://doi.org/10.1179/174313206X154012
Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogs: effect on vanilloid VR1 receptors and one cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845–852. https://doi.org/10.1038/sj.bjp.0704327
Borges RS, Batista J Jr, Viana RB, Baetas AC, Orestes E, Andrade MA, Honório KM, da Silva AB (2013) Understanding the molecular aspects of tetrahydrocannabinol and cannabidiol as antioxidants. Molecules 18:12663–12674. https://doi.org/10.3390/molecules181012663
Braida D, Pegorini S, Arcidiacono MV, Consalez GG, Croci L, Sala M (2003) Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci Lett 346:61–64. https://doi.org/10.1016/s0304-3940(03)00569-x
Britch SC, Babalonis S, Walsh SL (2021) Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology 238:9–28. https://doi.org/10.1007/s00213-020-05712-8
Campbell BCV, Khatri P (2020) Stroke. Lancet 396:129–142. https://doi.org/10.1016/S0140-6736(20)31179-X
Campbell B, De Silva DA, Macleod MR, Coutts SB, Schwamm LH, Davis SM, Donnan GA (2019) Ischaemic stroke. Nat Ver Dis Primers 5:70. https://doi.org/10.1038/s41572-019-0118-8
Campos AC, Fogaça MV, Sonego AB, Guimarães FS (2016) Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res 112:119–127. https://doi.org/10.1016/j.phrs.2016.01.033
Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez-Orgado J (2010) The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 37:434–440. https://doi.org/10.1016/j.nbd.2009.10.023
Catanese L, Tarsia J, Fisher M (2017) Acute ischemic stroke therapy overview. Circ Res 120:541–558. https://doi.org/10.1161/CIRCRESAHA.116.309278
Cechetti F, Worm PV, Pereira LO, Siqueira IR, Netto CA (2010) The modified 2VO ischemia protocol causes cognitive impairment similar to that induced by the standard method, but with a better survival rate. Braz J Med Biol Res 43:1178–1183. https://doi.org/10.1590/s0100-879x2010007500124
Ceprián M, Jiménez-Sánchez L, Vargas C, Barata L, Hind W, Martínez-Orgado J (2017) Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke. Neuropharmacology 116:151–159. https://doi.org/10.1016/j.neuropharm.2016.12.017
Ceprián M, Vargas C, García-Toscano L, Penna F, Jiménez-Sánchez L, Achicallende S, Elezgarai I, Grandes P, Hind W, Pazos MR, Martínez-Orgado J (2019) Cannabidiol administration prevents hypoxia-ischemia-induced hypomyelination in newborn rats. Front Pharmacol 10:1131. https://doi.org/10.3389/fphar.2019.01131
Chung H, Fierro A, Pessoa-Mahana CD (2019) Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: an in silico study. PLoS ONE 14:e0220025. https://doi.org/10.1371/journal.pone.0220025
Citti C, Braghiroli D, Vandelli MA, Cannazza G (2018) Pharmaceutical and biomedical analysis of cannabinoids: a critical review. J Pharm Biomed Anal 147:565–579. https://doi.org/10.1016/j.jpba.2017.06.003
Cristino L, Bisogno T, Di Marzo V (2020) Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Ver Neurol 16:9–29. https://doi.org/10.1038/s41582-019-0284-z
Cronin CA (2010) Intravenous tissue plasminogen activator for stroke: a review of the ECASS III results in relation to prior clinical trials. J Emerg Med 38:99–105. https://doi.org/10.1016/j.jemermed.2009.08.004
De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163:1479–1494. https://doi.org/10.1111/j.1476-5381.2010.01166.x
De Vos L, De Herdt V, Timmermans F (2019) Misdiagnosis or missed diagnosis: digging out the “Near-Field Clutter” artifact in a patient with stroke. CASE (Phila) 4:2–6. https://doi.org/10.1016/j.case.2019.10.007
Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE, American Heart Association Stroke Council and Council on Epidemiology and Prevention (2016) Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American heart association/American stroke association. Stroke 47:581–641. https://doi.org/10.1161/STR.0000000000000086
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, GWPCARE3 Study Group (2018) Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N Engl J Med 378:1888–1897. https://doi.org/10.1056/NEJMoa1714631
Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Ver Drug Discov 3:771–784. https://doi.org/10.1038/nrd1495
Dirnagl U (2012) Pathobiology of injury after stroke: the neurovascular unit and beyond. Ann N Y Acad Sci 1268:21–25. https://doi.org/10.1111/j.1749-6632.2012.06691.x
Dirnagl U, Iadecola C, Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22:391–397. https://doi.org/10.1016/s0166-2236(99)01401-0
Donkor ES (2018) Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life. Stroke Res Treat 2018:3238165. https://doi.org/10.1155/2018/3238165
Farag S, Kayser O (2017) The cannabis plant: botanical aspects. In: Preedy VR (ed) Handbook of Cannabis and Related Pathologies. Academic Press, London, pp 3–12. https://doi.org/10.1016/B978-0-12-800756-3.00001-6
Gale C, Statnikov Y, Jawad S, Uthaya SN, Modi N, Injuries B, expert working group, (2018) Neonatal brain injuries in England: population-based incidence derived from routinely recorded clinical data held in the National Neonatal Research Database. Arch Dis Child Fetal Neonatal Ed 103:F301–F306. https://doi.org/10.1136/archdischild-2017-313707
Garberg HT, Huun MU, Escobar J, Martinez-Orgado J, Løberg EM, Solberg R, Didrik Saugstad O (2016) Short-term effects of cannabidiol after global hypoxia-ischemia in newborn piglets. Pediatr Res 80:710–718. https://doi.org/10.1038/pr.2016.149
Garberg HT, Solberg R, Barlinn J, Martinez-Orgado J, Løberg EM, Saugstad OD (2017) High-dose cannabidiol induced hypotension after global hypoxia-ischemia in piglets. Neonatology 112:143–149. https://doi.org/10.1159/000471786
García-Chávez D, González-Burgos I, Letechipía-Vallejo G, López-Loeza E, Moralí G, Cervantes M (2008) Long-term evaluation of cytoarchitectonic characteristics of prefrontal cortex pyramidal neurons, following global cerebral ischemia and neuroprotective melatonin treatment, in rats. Neurosci Lett 448:148–152. https://doi.org/10.1016/j.neulet.2008.10.043
García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J (2020) Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules 10:1575. https://doi.org/10.3390/biom10111575
GBD 2017 US Neurological Disorders Collaborators (2021) Burden of neurological disorders across the us from 1990–2017: a global burden of disease study. JAMA Neurol 78:165–176. https://doi.org/10.1001/jamaneurol.2020.4152
Gennaro M, Mattiello A, Pizzorusso T (2019) Rodent models of developmental ischemic stroke for translational research: strengths and weaknesses. Neural Plast 2019:5089321. https://doi.org/10.1155/2019/5089321
George PM, Steinberg GK (2015) Novel stroke therapeutics: unraveling stroke pathophysiology and its impact on clinical treatments. Neuron 87:297–309. https://doi.org/10.1016/j.neuron.2015.05.041
Greco P, Nencini G, Piva I, Scioscia M, Volta CA, Spadaro S, Neri M, Bonaccorsi G, Greco F, Cocco I, Sorrentino F, D’Antonio F, Nappi L (2020) Pathophysiology of hypoxic-ischemic encephalopathy: a review of the past and a view on the future. Acta Neurol Belg 120:277–288. https://doi.org/10.1007/s13760-020-01308-3
Gulyás B, Tóth M, Schain M, Airaksinen A, Vas A, Kostulas K, Lindström P, Hillert J, Halldin C (2012) Evolution of microglial activation in ischaemic core and peri-infarct regions after stroke: a PET study with the TSPO molecular imaging biomarker [((11))C]vinpocetine. J Neurol Sci 320:110–117. https://doi.org/10.1016/j.jns.2012.06.026
Haj-Dahmane S, Shen RY (2011) Modulation of the serotonin system by endocannabinoid signaling. Neuropharmacology 61:414–420. https://doi.org/10.1016/j.neuropharm.2011.02.016
Haley MJ, Lawrence CB (2017) The blood-brain barrier after stroke: structural studies and the role of transcytotic vesicles. J Cereb Blood Flow Metab 37:456–470. https://doi.org/10.1177/0271678X16629976
Hamdy N, Eide S, Sun HS, Feng ZP (2020) Animal models for neonatal brain injury induced by hypoxic ischemic conditions in rodents. Exp Neurol 334:113457. https://doi.org/10.1016/j.expneurol.2020.113457
Hardy K (2020) Paleomedicine and the evolutionary context of medicinal plant use. Rev Bras Farmacogn 31:1–15. https://doi.org/10.1007/s43450-020-00107-4
Hayakawa K, Mishima K, Abe K, Hasebe N, Takamatsu F, Yasuda H, Ikeda T, Inui K, Egashira N, Iwasaki K, Fujiwara M (2004) Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. NeuroReport 15:2381–2385. https://doi.org/10.1097/00001756-200410250-00016
Hayakawa K, Mishima K, Nozako M, Hazekawa M, Irie K, Fujioka M, Orito K, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M (2007a) Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. J Neurochem 102:1488–1496. https://doi.org/10.1111/j.1471-4159.2007.04565.x
Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M (2007b) Repeated treatment with cannabidiol but not delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology 52:1079–1087. https://doi.org/10.1016/j.neuropharm.2006.11.005
Hayakawa K, Mishima K, Irie K, Hazekawa M, Mishima S, Fujioka M, Orito K, Egashira N, Katsurabayashi S, Takasaki K, Iwasaki K, Fujiwara M (2008) Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 55:1280–1286. https://doi.org/10.1016/j.neuropharm.2008.06.040
Hayakawa K, Irie K, Sano K, Watanabe T, Higuchi S, Enoki M, Nakano T, Harada K, Ishikane S, Ikeda T, Fujioka M, Orito K, Iwasaki K, Mishima K, Fujiwara M (2009) Therapeutic time window of cannabidiol treatment on delayed ischemic damage via high-mobility group box1-inhibiting mechanism. Biol Pharm Bull 32:1538–1544. https://doi.org/10.1248/bpb.32.1538
Hermann DM, Kleinschnitz C (2019) Modeling vascular risk factors for the development of ischemic stroke therapies. Stroke 50:1310–1317. https://doi.org/10.1161/STROKEAHA.118.024673
Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, Gao Y, Chen J (2012) Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 43:3063–3070. https://doi.org/10.1161/STROKEAHA.112.659656
Iadecola C, Ross ME (1997) Molecular pathology of cerebral ischemia: delayed gene expression and strategies for neuroprotection. Ann NY Acad Sci 835:203–217. https://doi.org/10.1111/j.1749-6632.1997.tb48631.x
Karsy M, Brock A, Guan J, Taussky P, Kalani MY, Park MS (2017) Neuroprotective strategies and the underlying molecular basis of cerebrovascular stroke. Neurosurg Focus 42:E3. https://doi.org/10.3171/2017.1.FOCUS16522
Khaksar S, Bigdeli MR (2017a) Intra-cerebral cannabidiol infusion-induced neuroprotection is partly associated with the TNF-α/TNFR1/NF-кB pathway in transient focal cerebral ischaemia. Brain Inj 31:1932–1943. https://doi.org/10.1080/02699052.2017.1358397
Khaksar S, Bigdeli MR (2017b) Anti-excitotoxic effects of cannabidiol are partly mediated by enhancement of NCX2 and NCX3 expression in animal model of cerebral ischemia. Eur J Pharmacol 794:270–279. https://doi.org/10.1016/j.ejphar.2016.11.011
Khodanovich MYu, Kisel AA (2015) Animal models of cerebral ischemia. AIP Conf Proc 1688https://doi.org/10.1063/1.4936032
Knowland D, Arac A, Sekiguchi KJ, Hsu M, Lutz SE, Perrino J, Steinberg GK, Barres BA, Nimmerjahn A, Agalliu D (2014) Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke. Neuron 82:603–617. https://doi.org/10.1016/j.neuron.2014.03.003
Lafuente H, Alvarez FJ, Pazos MR, Alvarez A, Rey-Santano MC, Mielgo V, Murgia-Esteve X, Hilario E, Martinez-Orgado J (2011) Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs. Pediatr Res 70:272–277. https://doi.org/10.1203/PDR.0b013e3182276b11
Lafuente H, Pazos MR, Alvarez A, Mohammed N, Santos M, Arizti M, Alvarez FJ, Martinez-Orgado JA (2016) Effects of Cannabidiol and hypothermia on short-term brain damage in new-born piglets after acute hypoxia-ischemia. Front Neurosci 10:323. https://doi.org/10.3389/fnins.2016.00323
Lapchak PA, Zhang JH (2017) The high cost of stroke and stroke cytoprotection research. Transl Stroke Res 8:307–317. https://doi.org/10.1007/s12975-016-0518-y
Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2016) Biased type 1 Cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease. Mol Pharmacol 89:364–375. https://doi.org/10.1124/mol.115.101980
Larsen C, Shahinas J (2020) Dosage, efficacy and safety of Cannabidiol administration in adults: a systematic review of human trials. J Clin Med Res 12:129–141. https://doi.org/10.14740/jocmr4090
Lehtonen L, Gimeno A, Parra-Llorca A, Vento M (2017) Early neonatal death: a challenge worldwide. Semin Fetal Neonatal Med 22:153–160. https://doi.org/10.1016/j.siny.2017.02.006
Leker RR, Shoham E (2002) Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res Rev 39:55–73. https://doi.org/10.1016/s0165-0173(02)00157-1
León-Moreno LC, Castañeda-Arellano R, Rivas-Carrillo JD, Dueñas-Jiménez SH (2020) Challenges and improvements of developing an ischemia mouse model through bilateral common carotid artery occlusion. J Stroke Cerebrovasc Dis 29:104773. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104773
Li LX, Cheng YF, Lin HB, Wang C, Xu JP, Zhang HT (2011) Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats. Metan Brain Dis 26:37–47. https://doi.org/10.1007/s11011-011-9235-0
Li Y, Cao Y, Xiao J, Shang J, Tan Q, Ping F, Huang W, Wu F, Zhang H, Zhang X (2020) Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury. Cell Death Differ 27:2635–2650. https://doi.org/10.1038/s41418-020-0528-x
Liaw N, Liebeskind D (2020) Emerging therapies in acute ischemic stroke. F1000Res 9:F1000 Faculty Rev-546. https://doi.org/10.12688/f1000research.21100.1
Lindsay MP, Norrving B, Sacco RL, Brainin M, Hacke W, Martins S, Pandian J, Feigin V (2019) World Stroke Organization (WSO): global stroke fact sheet. Int J Stroke 14:806–817. https://doi.org/10.1177/1747493019881353
Liu YC, Tsai YH, Tang SC, Liou HC, Kang KH, Liou HH, Jeng JS, Fu WM (2018) Cytokine MFI enhances blood-brain barrier permeability: impact for therapy in ischemic stroke. Sci Rep 8:743. https://doi.org/10.1038/s41598-017-16927-9
Macrae IM (2011) Preclinical stroke research–advantages and disadvantages of the most common rodent models of focal ischaemia. Br J Pharmacol 164:1062–1078. https://doi.org/10.1111/j.1476-5381.2011.01398.x
Martínez-Orgado J, Fernández-López D, Lizasoain I, Romero J (2007) The seek of neuroprotection: introducing cannabinoids. Recent Pat CNS Drug Discov 2:131–139. https://doi.org/10.2174/157488907780832724
Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11S-19S. https://doi.org/10.1002/j.1552-4604.2002.tb05998.x
Mehta SL, Manhas N, Raghubir R (2007) Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 54:34–66. https://doi.org/10.1016/j.brainresrev.2006.11.003
Meyer E, Bonato JM, Mori MA, Mattos BA, Guimarães FS, Milani H, de Campos AC, de Oliveira R (2021) Cannabidiol confers neuroprotection in rats in a model of transient global cerebral ischemia: impact of hippocampal synaptic neuroplasticity. Mol Neurobiol [Epub ahead of print]. https://doi.org/10.1007/s12035-021-02479-7
Millar LJ, Shi L, Hoerder-Suabedissen A, Molnár Z (2017) Neonatal hypoxia ischaemia: mechanisms, models, and therapeutic challenges. Front Cell Neurosci 11:78. https://doi.org/10.3389/fncel.2017.00078
Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K, Fujiwara M (2005) Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 36:1077–1082. https://doi.org/10.1161/01.STR.0000163083.59201.34
Mohammed N, Ceprian M, Jimenez L, Pazos MR, Martínez-Orgado J (2017) Neuroprotective effects of Cannabidiol in hypoxic ischemic insult. The therapeutic window in newborn mice. CNS Neurol Disord Targets 16:102–108. https://doi.org/10.2174/1871527315666160927110305
Morelli MB, Offidani M, Alesiani F, Discepoli G, Liberati S, Olivieri A, Santoni M, Santoni G, Leoni P, Nabissi M (2014) The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. Int J Cancer 134:2534–2546. https://doi.org/10.1002/ijc.28591
Mori MA, Meyer E, Soares LM, Milani H, Guimarães FS, de Oliveira R (2017) Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia. Prog Neuropsychopharmacol Biol Psychiatry 75:94–105. https://doi.org/10.1016/j.pnpbp.2016.11.005
Mori MA, Meyer E, da Silva FF, Milani H, Guimarães FS, Oliveira R (2021) Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments. Eur J Neurosci 53:1738–1751. https://doi.org/10.1111/ejn.15134
Muller C, Morales P, Reggio PH (2019) Cannabinoid ligands targeting TRP channels. Front Mol Neurosci 15:487–518. https://doi.org/10.3389/fnmol.2018.00487
O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW (2006) 1,026 experimental treatments in acute stroke. Ann Neurol 59:467–477. https://doi.org/10.1002/ana.20741
O’Sullivan SE (2016) An update on PPAR activation by cannabinoids. Br J Pharmacol 173:1899–1910. https://doi.org/10.1111/bph.13497
Pazos MR, Cinquina V, Gómez A, Layunta R, Santos M, Fernández-Ruiz J, Martínez-Orgado J (2012) Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. Neuropharmacology 63:776–783. https://doi.org/10.1016/j.neuropharm.2012.05.034
Pazos MR, Mohammed N, Lafuente H, Santos M, Martínez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Martínez-Orgado J (2013) Mechanisms of Cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology 71:282–291. https://doi.org/10.1016/j.neuropharm.2013.03.027
Peres FF, Diana MC, Levin R, Suiama MA, Almeida V, Vendramini AM, Santos CM, Zuardi AW, Hallak J, Crippa JÁ, Abílio VC (2018) Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia. Front Pharmacol 9:901. https://doi.org/10.3389/fphar.2018.00901
Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, Cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215. https://doi.org/10.1038/sj.bjp.0707442
Povroznik JM, Ozga JE, Vonder Haar C, Engler-Chiurazzi EB (2018) Executive (dys)function after stroke: special considerations for behavioral pharmacology. Behav Pharmacol 29:638–653. https://doi.org/10.1097/FBP.0000000000000432
Prakash R, Carmichael ST (2015) Blood-brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury. Curr Opin Neurol 28:556–564. https://doi.org/10.1097/WCO.0000000000000248
Rajsic S, Gothe H, Borba HH, Sroczynski G, Vujicic J, Toell T, Siebert U (2019) Economic burden of stroke: a systematic review on post-stroke care. Eur J Health Econ 20:107–134. https://doi.org/10.1007/s10198-018-0984-0
Raval AP, Bhatt A, Saul I (2009) Chronic nicotine exposure inhibits 17beta-estradiol-mediated protection of the hippocampal CA1 region against cerebral ischemia in female rats. Neurosci Lett 458:65–69. https://doi.org/10.1016/j.neulet.2009.04.021
Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, Vitoretti LB, Mariano-Souza DP, Quinteiro-Filho WM, Akamine AT, Almeida VI, Quevedo J, Dal-Pizzol F, Hallak JE, Zuardi AW, Crippa JA, Palermo-Neto J (2012) Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor. Eur J Pharmacol 678:78–85. https://doi.org/10.1016/j.ejphar.2011.12.043
Rodríguez-Muñoz M, Onetti Y, Cortés-Montero E, Garzón J, Sánchez-Blázquez P (2018) Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor. Mol Brain 11:51. https://doi.org/10.1186/s13041-018-0395-2
Rolls A, Shechter R, Schwartz M (2009) The bright side of the glial scar in CNS repair. Net Rev Neurosci 10:235–241. https://doi.org/10.1038/nrn2591
Ross RA (2009) The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30:156–163. https://doi.org/10.1016/j.tips.2008.12.004
Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037–1043. https://doi.org/10.1007/s11064-005-6978-1
Sales AJ, Crestani CC, Guimarães FS, Joca S (2018) Antidepressant-like effect induced by cannabidiol is dependent on brain serotonin levels. Prog Neuropsychotopharmacol Biol Psychiatry 86:255–261. https://doi.org/10.1016/j.pnpbp.2018.06.002
Sánchez-Gómez MV, Alberdi E, Ibarretxe G, Torre I, Matute C (2003) Caspase-dependent and caspase-independent oligodendrocyte death mediated by AMPA and kainate receptors. J Neurosci 23:9519–9528. https://doi.org/10.1523/JNEUROSCI.23-29-09519.2003
Sánchez-Gómez MV, Alberdi E, Pérez-Navarro E, Alberch J, Matute C (2011) Bax and calpain mediate excitotoxic oligodendrocyte death induced by activation of both AMPA and kainate receptors. J Neurosci 31:2996–3006. https://doi.org/10.1523/JNEUROSCI.5578-10.2011
Sarma ND, Waye A, ElSohly MA, Brown PN, Elzinga S, Johnson HE, Marles RJ, Melanson JE, Russo E, Deyton L, Hudalla C, Vrdoljak GA, Wurzer JH, Khan IA, Kim NC, Giancaspro GI (2020) Cannabis inflorescence for medical purposes: USP considerations for quality attributes. J Nat Prod 83:1334–1351. https://doi.org/10.1021/acs.jnatprod.9b01200
Schiavon AP, Soares LM, Bonato JM, Milani H, Guimarães FS, Weffort de Oliveira RM (2014) Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotox Res 26:307–316. https://doi.org/10.1007/s12640-014-9457-0
Seeman P (2016) Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Transl Psychiatry 6:e920. https://doi.org/10.1038/tp.2016.195
Sommer CJ (2017) Ischemic stroke: experimental models and reality. Acta Neuropathol 133:245–261. https://doi.org/10.1007/s00401-017-1667-0
Stinear CM, Barber PA (2020) Neurophysiology to guide acute stroke treatment. Clin Neurophysiol 131:2284–2285. https://doi.org/10.1016/j.clinph.2020.06.014
Syed YY, McKeage K, Scott LJ (2014) Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs 74:563–578. https://doi.org/10.1007/s40265-014-0197-5
Tham M, Yilmaz O, Alaverdashvili M, Kelly M, Denovan-Wright EM, Laprairie RB (2019) Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol 176:1455–1469. https://doi.org/10.1111/bph.14440
Traystman RJ (2003) Animal models of focal and global cerebral ischemia. ILAR J 44:85–95. https://doi.org/10.1093/ilar.44.2.85
Vallée A, Lecarpentier Y, Guillevin R, Vallée JN (2017) Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer’s disease. Acta Biocheim Biophys Sin 49:853–866. https://doi.org/10.1093/abbs/gmx073
Valvassori SS, Bavaresco DV, Scaini G, Varela RB, Streck EL, Chagas MH, Hallak JE, Zuardi AW, Crippa JA, Quevedo J (2013) Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain. Braz J Psychiatry 35:380–386. https://doi.org/10.1590/1516-4446-2012-0886
Wang G, Guo Q, Hossain M, Fazio V, Zeynalov E, Janigro D, Mayberg MR, Namura S (2009) Bone marrow-derived cells are the major source of MMP-9 contributing to blood-brain barrier dysfunction and infarct formation after ischemic stroke in mice. Brain Res 1294:183–192. https://doi.org/10.1016/j.brainres.2009.07.070
Wang Y, Zhao Z, Chow N, Rajput PS, Griffin JH, Lyden PD, Zlokovic BV (2013) Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats. Stroke 44:3529–3536. https://doi.org/10.1161/STROKEAHA.113.003350
White CM (2019) A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. J Clin Pharmacol 59:923–934. https://doi.org/10.1002/jcph.1387
Yıldız EP, Ekici B, Tatlı B (2017) Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment. Expert Rev Neurother 17:449–459. https://doi.org/10.1080/14737175.2017.1259567
Funding
This work is based on a collaboration supported by Serviço Alemão de Intercâmbio Acadêmico (DAAD)/Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)—PROBRAL, University of Maringá, Maringá, Brazil, and University of Saarland, Homburg, Germany. EM benefits from a PhD scholarship provided by CAPES and BAM benefits from a PhD scholarship provided by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
Author information
Authors and Affiliations
Contributions
Both EM and RMWO wrote the article. BAM prepared the supplementary material and figures. FK made a critical revision of the article before submission to the Journal. All authors discussed and commented on the manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no competing interests.
Additional information
This article is part of a Special Issue to celebrate the 35th anniversary of the Brazilian Journal of Pharmacognosy
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Meyer, E., de Mattos, B.A., Kirchhoff, F. et al. Neuroprotective Effects of Cannabidiol Under Cerebral Ischemic Conditions. Rev. Bras. Farmacogn. 31, 579–591 (2021). https://doi.org/10.1007/s43450-021-00199-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43450-021-00199-6